T-lymphocyte receptor and immunotherapy are based on the use of T-lymphocytes and immune lymphocytes to fight cancer

摘要

The invention is aimed at the manufacturer of antigen recognition agent of tumor related antigen (TAA)Especially for the more common antiques in melanoma (PrME). In particular, the invention provides molecules based on new T-cell receptors that have selectivity and specifications for antigens of the invention expressed in tumors. TCR, as well as the resulting fragments combined with TAA, are used to diagnose, treat and prevent tumor diseases represented by TAA. In addition, nucleic acids are provided for the preparation of anti-virus components for inventions of vehicles including these nucleic acids,Reduced cells refer to known antigen builders and pharmacological components including compounds of invention.